1. Home
  2. SGN vs INDP Comparison

SGN vs INDP Comparison

Compare SGN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Signing Day Sports Inc.

SGN

Signing Day Sports Inc.

HOLD

Current Price

$0.48

Market Cap

4.7M

Sector

N/A

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.59

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGN
INDP
Founded
2019
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SGN
INDP
Price
$0.48
$2.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
179.7K
1.8M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$366,344.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$1.65
52 Week High
$7.24
$47.60

Technical Indicators

Market Signals
Indicator
SGN
INDP
Relative Strength Index (RSI) 20.70 51.49
Support Level $1.11 $2.46
Resistance Level $1.13 $3.06
Average True Range (ATR) 0.08 0.30
MACD -0.06 0.05
Stochastic Oscillator 18.82 51.08

Price Performance

Historical Comparison
SGN
INDP

About SGN Signing Day Sports Inc.

Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: